Repligen initiated with a Hold at Canaccord | Nasdaq

Dec 16, 2024 · Canaccord initiated coverage of Repligen (RGEN) with a Hold rating and $165 price target The company delivers configurable bioprocessing products and systems that are …

$165
OFF

Repligen Initiated With A Hold At Canaccord | Nasdaq

2 weeks from now

Dec 16, 2024 · Canaccord initiated coverage of Repligen (RGEN) with a Hold rating and $165 price target The company delivers configurable bioprocessing products and systems that are …

nasdaq.com

$165.00
OFF

Canaccord Genuity Group Begins Coverage On Repligen …

2 weeks from now

Dec 17, 2024 · Canaccord Genuity Group began coverage on Repligen in a report on Tuesday. They issued a "hold" rating and a $165.00 target price on the stock. Royal Bank of Canada …

marketbeat.com

$165.00
OFF

Repligen (NASDAQ:RGEN) Raised To Hold At StockNews.com

2 weeks from now

Jan 4, 2025 · Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock.

etfdailynews.com

$165
OFF

Canaccord Initiates Repligen With Hold, Sets $165 Price Target

2 weeks from now

Dec 16, 2024 · On Monday, Canaccord Genuity began coverage on shares of Repligen (NASDAQ:RGEN) Corporation (NASDAQ:RGEN), a company that specializes in …

investing.com

$165
OFF

Canaccord Initiates Repligen With Hold, Sets $165 Price Target

2 weeks from now

Dec 16, 2024 · On Monday, Canaccord Genuity (TSX: CF) began coverage on shares of Repligen (NASDAQ: RGEN) Corporation (NASDAQ:RGEN), a company that specializes in …

investing.com

$185.20
OFF

Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target At $185.20

2 weeks from now

11 hours ago · Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock.

etfdailynews.com

$165.00
OFF

Repligen (NASDAQ:RGEN) Research Coverage Started At …

2 weeks from now

Dec 20, 2024 · Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday. They issued a “hold” rating and a $165.00 price objective on the stock.

defenseworld.net

$165
OFF

Canaccord Initiates Repligen With Hold, Sets $165 Price Target

2 weeks from now

On Monday, Canaccord Genuity began coverage on shares of Repligen (NASDAQ: RGEN) Corporation (NASDAQ:RGEN), a company that specializes in bioprocessing products and …

investing.com

$165
OFF

Canaccord Initiates Repligen With Hold, Sets $165 Price Target

2 weeks from now

Canaccord initiates Repligen with Hold, sets $165 price target

investing.com

$165.00
OFF

Repligen (NASDAQ:RGEN) Upgraded At StockNews.com

2 weeks from now

They issued a "hold" rating and a $165.00 price objective on the stock. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They set a …

marketbeat.com

$207.00
OFF

RBC Capital Keeps Their Buy Rating On Repligen (RGEN)

2 weeks from now

1 day ago · RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on January 10 and set a price target of $207.00. The company’s shares …

businessinsider.com

54%
OFF

Repligen (RGEN) Stock Forecast And Price Target 2025 - MarketBeat

2 weeks from now

6 days ago · Canaccord Genuity Group. ... Initiated Coverage: Hold: $165.00 +2.54%: 11/14/2024: Wolfe Research. 3 of 5 stars: D. Schenkel Subscribe to MarketBeat All Access for …

marketbeat.com

$165.00
OFF

StockNews.com Downgrades Repligen (NASDAQ:RGEN) To Sell

2 weeks from now

Dec 19, 2024 · Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday. They issued a "hold" rating and a $165.00 price objective on the stock. Finally, Royal …

marketbeat.com

FAQs about Repligen initiated with a Hold at Canaccord | Nasdaq Coupon?

Is Repligen a good stock to buy?

Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. ...

Is Canaccord Genuity Group a good stock to buy?

The firm set a “hold” rating and a $165.00 price target on the biotechnology company’s stock. Canaccord Genuity Group’s target price indicates a potential upside of 11.99% from the stock’s previous close. ...

Should you buy Repligen co (RGEN) stock?

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. ...

Should you buy Repligen (Repligen)?

McNamara covers the Healthcare sector, focusing on stocks such as Hologic, Illumina, and QuidelOrtho. According to TipRanks, McNamara has an average return of -11.5% and a 33.55% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Repligen with a $198.17 average price target. ...

What is the average 12 month price target for Repligen?

The average 12 month price target among analysts that have issued ratings on the stock in the last year is $185.20. A number of equities analysts have issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. ...

How much will Repligen (Repligen) earn per share?

On average, sell-side analysts expect that Repligen will post 1.54 earnings per share for the current year. (Get Free Report Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. ...